drugset / Trial / NCT01019616
Alternative Non-cross-resistant Adjuvant Chemotherapy for Operable Breast Cancer Non-response to Primary Chemotherapy
Phase 3
Unknown
400 enrolled
Tao OUYANG
307 Hospital of PLA · collabBeijing Chao Yang Hospital · collabBeijing Municipal Science & Technology Commission · collabChinese Academy of Medical Sciences · collabPeking Union Medical College Hospital · collabPeking University First Hospital · collabPeking University People's Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this phase Ⅲ, multi-center, prospective, open-label, randomized,controlled study is to determine whether alternative non-cross-resistant adjuvant chemotherapy can increase distant disease free survival(DDFS) in operable patients non-response to primary chemotherapy.
Timeline
- Start
- 2011-03-04
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | — | — |